Insulin-induced microvascular activity in patients with essential hypertension: possible interactions with angiotensin II - Amendement 24-09-2007

Insulin-induced microvascular activity in patients with essential hypertension: possible interactions with angiotensin II - Amendement 24-09-2007 - Role of angII in insulin-induced vasodilation - Amendement 24-09-07

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON30618

Enrollment

Registered

2006-09-19

Start date

2007-02-28

Completion date

Unknown

Last updated

2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

high blood pressure hypertension

Interventions

Amendement: Angiotensin II and phenylephrine will be infused intravenously. During the visit 6x5 ml venous blood samples will be taken, blood pressure and heart rate will be monitored.

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Age 18-60, Caucasian, blood pressure

Exclusion criteria

Exclusion criteria: Obesity: BMI > 27 kg/m2, cardiovascular disease (stroke, coronary artery disease, peripheral vascular disease, heart failure), impaired glucose tolerance or diabetes mellitus according to the criteria of the ADA, smoking, alcohol use >4 U/day, use of medication (antihypertensive drugs, lipid lowering drugs, corticosteroids, NSAIDs), pregnancy. Having contact lenses is also an exclusion criteria.

Design outcomes

Primary

Measure	Time frame
Amendement: - blood pressure	—

Secondary

Measure	Time frame
Amendement: - plasma angiotensinII levels	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)